We came across a bullish thesis on Biogen Inc. on Investing With Purpose’s Substack. In this article, we will summarize the bulls’ thesis on BIIB. Biogen Inc.'s share was trading at $143.81 as of September 18th. BIIB’s trailing and forward P/E were 13.86 and 9.04 respectively according to Yahoo Finance.
[caption id="attachment_570721" align="aligncenter" width="750"]Biogen (BIIB) enters its July 31 Q2 earnings with investor focus on the rollout of its Alzheimer’s drug lecanemab and the durability of its multiple sclerosis...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.